Genmab
GMAB
219 hedge funds and large institutions have $1.23B invested in Genmab in 2024 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 69 increasing their positions, 93 reducing their positions, and 34 closing their positions.
1.16% more ownership
Funds ownership: 72.54% → 73.7% (+1.2%)
4% less funds holding
Funds holding: 227 → 219 (-8)
14% less capital invested
Capital invested by funds: $1.44B → $1.23B (-$208M)
21% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 34
26% less repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 93
74% less call options, than puts
Call options by funds: $178K | Put options by funds: $696K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$34.7M |
| 2 |
Two Sigma Investments
New York
|
+$13M |
| 3 |
DP
DDD Partners
Bellevue,
Washington
|
+$10M |
| 4 |
Two Sigma Advisers
New York
|
+$7.85M |
| 5 |
Goldman Sachs
New York
|
+$6.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HL
Harding Loevner
Bridgewater,
New Jersey
|
-$14.9M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$8.54M |
| 3 |
Schroder Investment Management Group
London,
United Kingdom
|
-$7.25M |
| 4 |
Royal London Asset Management
United Kingdom
|
-$4.98M |
| 5 |
Capital International Investors
Los Angeles,
California
|
-$4.12M |
GMAB Hedge Fund Activity: Q2 2024 in Review
219 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Genmab (GMAB) for Q2 2024, worth a combined $1.23B — down 14% from $1.44B a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of GMAB and 27 opened new positions — a net loss of 7 holders — while 93 trimmed existing stakes and 69 added.
The largest buyer was Citadel Advisors, adding an estimated $34.7M. The largest seller was Harding Loevner, cutting an estimated $14.9M.
- 219 institutional investors held Genmab (GMAB) as of Q2 2024, down from 227 in Q1 2024.
- Funds reported $1.23B of Genmab stock for Q2 2024, down 14% quarter-over-quarter.
- 27 funds opened new Genmab positions in Q2 2024 and 34 closed out, a net change of -7 holders.
- The largest Genmab buyer in Q2 2024 was Citadel Advisors, an estimated $34.7M added.
- The largest Genmab seller in Q2 2024 was Harding Loevner, an estimated $14.9M sold.
Based on aggregated 13F filings for Q2 2024.